A Study to Examine if People Without HFpEF Display Less Visceral Adipose Tissue (VAT) Compared to Patients with Diagnosed HFpEF

Overview

About this study

The purpose of this study is to examine whether people without HFpEF display less visceral adipose tissue (VAT) compared to patients with diagnosed HFpEF.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Adult Participants, non-HFpEF (25 prospectively enrolled)
    1. Adult controls (>18 years) age, sex, and BMI matched without signs or symptoms of heart failure, confirmed via limited echocardiogram and physical examination.
  2. Data retrospectively collected from 25 Adult Participants with HFpEF (≥3 months), age 40-85 years who were enrolled in study 16-001467, defined by:
    1. Signs and symptoms of HF (dyspnea, fatigue), normal left ventricular (LV) EF (≥50% within 12 months of enrollment), and objective evidence of HF as met by at least 1 of the following 4 criteria:
      1. Hospitalization for decompensated HF in the past year but not within the past 30 days;
      2. Invasively-documented elevated pulmonary capillary wedge pressures (PCWP) at rest (>15 mmHg) or with exercise (≥25 mmHg) at catheterization performed in the evaluation of dyspnea;
      3. Elevated NT-proBNP (>400 pg/mL) or BNP (>200 pg/mL);
      4. Echocardiographic evidence of HFpEF based upon current diagnostic guidelines(≥2 of the following: [a] E/e’≥15, [b] ≥moderate left atrial enlargement, [c] PASP >35 mm Hg).

Exclusion Criteria:

  1. Adult Participants, non-HFpEF
    1. Signs and symptoms of HF (dyspnea, fatigue), reduced left ventricular (LV) EF (≤50% within 12 months of enrollment), and objective evidence of HF as met by at least 1 of the following 4 criteria:
    2. Hospitalization for decompensated HF in the past year but not within the past 30 days;
    3. Invasively-documented elevated pulmonary capillary wedge pressures (PCWP) at rest (>15 mmHg) or with exercise (≥25 mmHg) at catheterization performed in the evaluation of dyspnea;
    4. Elevated NT-proBNP (>400 pg/mL) or BNP (>200 pg/mL);
    5. Echocardiographic evidence of HFpEF based upon current diagnostic guidelines40 (≥2 of the following: [a] E/e’≥15, [b] ≥moderate left atrial enlargement, [c] PASP >35 mm Hg).
  2. Data retrospectively collected from 25 Adult Participants with HFpEF (≥3 months), age 40-85 years who were enrolled in study 16-001467, defined by:
    1. Inability/unwillingness to engage in ET 
    2. Recent (<1 months) HF hospitalization 
    3. Concomitant treatment with organic nitrates or phosphodiesterase 5 inhibitors 
    4. Prior EF <50%, BMI <20 or >50 kg/m2 
    5. Acute coronary syndrome or revascularization within 3 months
    6. Infiltrative, hypertrophic, or radiation-induced cardiomyopathies 
    7. Constrictive pericarditis 
    8. Dyspnea felt to be due to primary lung disease or myocardial ischemia 
    9. Severe anemia (Hgb <8.0) 
    10. Systolic BP <110 mm Hg at consent  
    11. Recent (<30 day) change in diuretics/vasoactive medications 
    12. Significant left-sided valvular heart disease (>mild stenosis, >moderate regurgitation) 
    13. Complex congenital heart disease 
    14. Severe renal (estimated GFR<30) or hepatic disease

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Thomas Olson, Ph.D., M.S.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20420471

Mayo Clinic Footer